• Cancel
    Date：2026-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=921

    Recently, CAStar Foods, a leader in China’s biosynthetic human-derived bioactive protein industry, announced the closing of a Series A+ financing round worth several hundred million RMB. The company’s independently developed A60 bioactive peptide replicates rare core protein fragments found in breast milk, boasting immense potential in the fields of nutritional immunology and health. Proceeds from this financing round will be mainly allocated to advancing the industrialization of the company’s core functional protein/peptide products and their global market expansion. CEC Capital acted as the exclusive financial advisor to CAStar Foods for this transaction.

  • Cancel
    Date：2026-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=919

    Recently, MicroCyto announced the closing of a new round of equity financing worth nearly 300 million RMB. The investors include Beijing New Materials Industry Investment Fund, Beijing Medical and Health Industry Investment Fund, Zhongguancun Capital, and

  • Cancel
    Date：2025-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=917

    Refine Biology recently announced the closing of a several hundred million RMB Series C financing round. The round was led by Xingxiang Asset Management Group, with participation from Royal Power XMXYG Fund as a co-investor. Proceeds from this financing w

  • Cancel
    Date：2025-10

    Exclusive Financial Advisor

  • Cancel
    Date：2025-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=910

    CEC Capital announced today that its GP/LP service team, dedicated to the private equity secondary market, has successfully completed two significant transactions involving the exit of existing shares. These deals enabled clients to achieve large-scale li

  • Cancel
    Date：2025-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=908

    iRegene, a biotech company committed to becoming a global leader in universal chemically induced cell therapies, recently announced the successful completion of its Series B+ financing round. The round was jointly led by Northern Light Venture Capital, Ch

  • Cancel
    Date：2025-08

    Exclusive Financial Advisor to BridgeDP

  • Cancel
    Date：2025-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=904

    On the evening of June 30, 2025, Suning.com (002024) announced that its first interim shareholders' meeting of 2025 had approved the Proposal on the Sale of Subsidiary Equity by Suning International Holding’s Subsidiary Carrefour China Holdings N.V. CEC Capital acted as the exclusive financial advisor to Suning.com for this transaction.

  • Cancel
    Date：2025-04

    Exclusive Financial Advisor to IREGENE